The global bulk-drug compounding market is set to experience significant growth over the next decade, driven by increasing demand for customized medications amid persistent drug shortages. Estimated to be worth USD 11,887.6 million in 2024, the market is projected to surge to USD 19,735.7 million by 2034, growing at a steady compound annual growth rate (CAGR) of 5.2% during the forecast period.
Bulk-drug compounding generated revenue of USD 11,300.0 million in 2023, showcasing the critical role compounding pharmacies play in addressing gaps in the pharmaceutical supply chain.
A Lifeline Amid Drug Shortages:
Compounding pharmacies are uniquely positioned to mitigate the challenges posed by drug shortages. They provide customized medication solutions when commercial supplies fall short, ensuring patients have continued access to essential therapies. This is particularly vital for sterile injectables and other critical treatments where uninterrupted supply is paramount.
Drug shortages are often caused by a range of factors, including:
- Manufacturing issues: Disruptions or inefficiencies in production lines.
- Supply chain problems: Delays or bottlenecks in transportation and distribution.
- Increased demand: Surges in patient needs outpacing available supply.
- Regulatory hurdles: Stricter compliance requirements leading to slower output.
By stepping in to fill these gaps, compounding pharmacies not only enhance patient care but also play a pivotal role in maintaining public health standards.
Market Growth Drivers:
The increasing reliance on compounded drugs is driven by a growing recognition of their flexibility and necessity. Key factors fueling market expansion include:
- Rising prevalence of chronic diseases requiring tailored therapeutic approaches.
- An aging population with specific medication needs.
- Advancements in compounding techniques enabling safer and more effective formulations.
Outlook for 2034:
As global healthcare systems grapple with dynamic challenges, the bulk-drug compounding market is poised to emerge as a cornerstone of pharmaceutical resilience. The projected growth underscores the importance of continued innovation and investment in compounding technologies to meet the evolving needs of patients worldwide.
Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!
Key Takeaways:
- The global sales of bulk-drug compounding are forecasted to grow from USD 11,887.6 million in 2024 to USD 19,735.7 million by 2034, reflecting a CAGR of 5.2% over the 2024–2034 period.
- North America leads the growth, with the USA expected to achieve a 5.6% value CAGR from 2024 to 2034.
- Canada is projected to experience a 4.3% value CAGR over the same period.
- In Europe, Germany and France are expected to see significant growth, with projected CAGRs of 4.4% and 4.1%, respectively.
- China’s bulk-drug compounding market is expected to expand at a 3.2% value CAGR.
- The UK’s market is anticipated to grow at a 5.0% value CAGR, highlighting strong regional demand.
- South Korea and India are expected to witness slower growth with projected CAGRs of 2.9% and 2.5%, respectively.
This growth trajectory underscores the rising global demand for bulk-drug compounding, driven by expanding pharmaceutical needs across various regions.
Competitive Landscape:
The bulk-drug compounding industry is witnessing significant investments in research and development, driving innovation by differentiating products with advanced features and improving patient outcomes. A major strategic focus for companies in this sector is forming strategic partnerships to enhance their product portfolios and expand their global market presence.
Recent Industry Developments in the Bulk-Drug Compounding Market
- On May 19, 2023, Fagron Academy entered into a partnership with Gates Healthcare to enhance support for compounding pharmacies. This collaboration aims to provide valuable educational resources and training, equipping compounding pharmacies to better meet the evolving needs of healthcare providers and patients.
- In 2023, Fagron also acquired London Specialist Pharmacy, marking a pivotal step in expanding its presence in the United Kingdom. This acquisition enables Fagron to enter the UK compounding market and further diversify its operations in the EMEA region, aligning with the company’s disciplined acquisition strategy to strengthen its service offerings and market position.
Key Players of Bulk-Drug Compounding Market:
- Fogron
- B.Broun Melsungen AG
- Nephron Pharmaceuticals Corporaiton
- Athenex Pharmaceutical Division
- QuVa Pharma
- Fresenius Kabi
- Central Admixture Pharmacy Services Inc.
- PharMEDium
- Avella Speciality Pharmacy
- ImprimisRx
- Edge Pharma
- SCA Pharma
- New England Compounding Center
- Bellevue Pharmacy
- Pharmazone
Key Segments of Bulk-Drug Compounding Market:
By Product:
In terms of product, the industry is divided into sterile compounding and non-sterile compounding.
By Form:
In terms of form, the industry is segregated into oral, topical, injectable, ophthalmic and suppositories.
By Therapeutic Area:
In terms of therapeutic area, the industry is segregated into cardiovascular, oncology, endocrinology, pain management, infectious diseases, neurology, dermatology and others.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube